Teva Pharmaceutical Industries (NYSE:TEVA) Shares Gap Down – What’s Next?

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)’s share price gapped down prior to trading on Monday . The stock had previously closed at $30.08, but opened at $29.09. Teva Pharmaceutical Industries shares last traded at $29.5250, with a volume of 858,774 shares changing hands.

Analyst Ratings Changes

Several analysts recently weighed in on TEVA shares. The Goldman Sachs Group lifted their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Scotiabank lifted their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a report on Thursday, January 29th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Finally, Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $37.67.

Teva Pharmaceutical Industries Trading Down 1.6%

The company’s 50 day simple moving average is $32.04 and its 200 day simple moving average is $28.01. The firm has a market cap of $33.74 billion, a price-to-earnings ratio of 24.45, a P/E/G ratio of 10.13 and a beta of 0.76. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.04 and a quick ratio of 0.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. The business had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. As a group, research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Placid Jover sold 14,150 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $448,130.50. Following the completion of the transaction, the insider owned 6,774 shares in the company, valued at approximately $214,532.58. The trade was a 67.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the business’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 920,901 shares of company stock valued at $30,056,789. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. Global Retirement Partners LLC increased its stake in shares of Teva Pharmaceutical Industries by 27.3% during the 4th quarter. Global Retirement Partners LLC now owns 1,360 shares of the company’s stock worth $42,000 after purchasing an additional 292 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Captrust Financial Advisors now owns 14,715 shares of the company’s stock worth $459,000 after purchasing an additional 302 shares in the last quarter. Banque Cantonale Vaudoise increased its stake in shares of Teva Pharmaceutical Industries by 6.3% during the 4th quarter. Banque Cantonale Vaudoise now owns 5,133 shares of the company’s stock worth $160,000 after purchasing an additional 306 shares in the last quarter. Ethic Inc. increased its stake in shares of Teva Pharmaceutical Industries by 1.8% during the 4th quarter. Ethic Inc. now owns 18,127 shares of the company’s stock worth $566,000 after purchasing an additional 325 shares in the last quarter. Finally, Allworth Financial LP increased its stake in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after purchasing an additional 329 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.